Rehab Clinic Busted by DEA for Sloppy Narcotics Paperwork
Published Date: 10/2/2025
Notice
Summary
Hollywood Medical Rehabilitation Care, Inc. lost its DEA registration because it didn’t keep proper records for narcotic treatments. The company missed important deadlines to respond, so the government shut down its license starting December 2024. This means they can’t legally handle controlled substances anymore, affecting their business and patients relying on their care.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Revokes Clinic's Controlled‑Substance License
If you are a patient of Hollywood Medical Rehabilitation Care in Los Angeles, the DEA revoked its Certificate of Registration No. RH0554053. The revocation is effective November 3, 2025, and means the clinic may no longer legally possess, dispense, or handle controlled substances.
Clinic's Registration Revoked; Renewals Denied
Hollywood Medical Rehabilitation Care, Inc. had DEA Certificate of Registration No. RH0554053 revoked and the DEA denied any pending renewal, modification, or other registration applications for the company in California. The Order is effective November 3, 2025, preventing the business from legally operating with controlled substances.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
Previous / Next Documents
Previous: 2025-19379 — Government Owned Inventions Available for Licensing and/or Collaboration: Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology
The National Cancer Institute has a cool new gadget that uses sound waves to tag and sort cells automatically. They’re looking for partners or companies to help bring this tech to life and make it available for research and medical use. This is a great chance to team up with the government and speed up important health discoveries!
Next: 2025-19380 — Notice Pursuant to the National Cooperative Research and Production Act of 1993-The Open Group, L.L.C.
The Open Group just updated its membership with new companies and universities from around the world, including places like Hungary, Australia, and the U.S. This change keeps special legal protections in place that limit antitrust lawsuit damages to actual losses. These updates were officially filed on August 22, 2025, and affect all members involved in this tech and research collaboration.